Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
Fletcher K, Cortellini A, Ganta T, Kankaria R, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Presley CJ, Owen DH, Abou Alaiwi S, Nassar AH, Lamberti G, Perrone F, Buti S, Giusti R, Filetti M, Vanella V, Mallardo D, Sussman TA, Galetta D, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Nebhan C, Berg S, Choueiri TK, Marron TU, Wang Y, Naqash AR, Johnson DB. Fletcher K, et al. Among authors: lamberti g. Cancer Lett. 2024 Aug 1;596:217001. doi: 10.1016/j.canlet.2024.217001. Epub 2024 Jun 3. Cancer Lett. 2024. PMID: 38838764 Free article.
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
Alessi JV, Elkrief A, Ricciuti B, Wang X, Cortellini A, Vaz VR, Lamberti G, Frias RL, Venkatraman D, Fulgenzi CAM, Pecci F, Recondo G, Di Federico A, Barrichello A, Park H, Nishino M, Hambelton GM, Egger JV, Ladanyi M, Digumarthy S, Johnson BE, Christiani DC, Lin X, Gainor JF, Lin JJ, Pinato DJ, Schoenfeld AJ, Awad MM. Alessi JV, et al. Among authors: lamberti g. J Thorac Oncol. 2023 Jun;18(6):731-743. doi: 10.1016/j.jtho.2023.01.091. Epub 2023 Feb 10. J Thorac Oncol. 2023. PMID: 36775193 Free PMC article.
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
Elkrief A, Alessi JMV, Ricciuti B, Brown S, Rizvi H, Preeshagul IR, Wang X, Pecci F, Di Federico A, Lamberti G, Egger JV, Chaft JE, Rudin CM, Riely GJ, Kris MG, Ladanyi M, Chen Y, Hellmann MD, Shen R, Awad MM, Schoenfeld AJ. Elkrief A, et al. Among authors: lamberti g. J Immunother Cancer. 2023 Jul;11(7):e006994. doi: 10.1136/jitc-2023-006994. J Immunother Cancer. 2023. PMID: 37487667 Free PMC article.
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
Elkrief A, Riccuiti B, Alessi JV, Fei T, Kalvin HL, Egger JV, Rizvi H, Thummalapalli R, Lamberti G, Plodkowski A, Hellmann MD, Kris MG, Arcila ME, Baine MK, Rudin CM, Lito P, Ladanyi M, Schoenfeld AJ, Riely GJ, Awad MM, Arbour KC. Elkrief A, et al. Among authors: lamberti g. Oncologist. 2023 Nov 2;28(11):978-985. doi: 10.1093/oncolo/oyad197. Oncologist. 2023. PMID: 37589215 Free PMC article.
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.
Di Federico A, Alden SL, Smithy JW, Ricciuti B, Alessi JV, Wang X, Pecci F, Lamberti G, Gandhi MM, Vaz VR, Spurr LF, Sholl LM, Pfaff KL, Rodig SJ, Li YY, Cherniack AD, Nishino M, Johnson BE, Awad MM. Di Federico A, et al. Among authors: lamberti g. Ann Oncol. 2024 Oct;35(10):902-913. doi: 10.1016/j.annonc.2024.06.014. Epub 2024 Jun 29. Ann Oncol. 2024. PMID: 38950679
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab.
Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi JV, Lamberti G, Gandhi M, Di Federico A, Pecci F, Wang X, Makarem M, Hidalgo Filho CM, Gorria T, Saini A, Pabon C, Lindsay J, Pfaff KL, Welsh EL, Nishino M, Sholl LM, Rodig S, Kilickap S, Rietschel P, McIntyre DA, Pouliot JF, Altan M, Gainor JF, Heymach JV, Schoenfeld AJ, Awad MM. Ricciuti B, et al. Among authors: lamberti g. JTO Clin Res Rep. 2024 Apr 12;5(9):100675. doi: 10.1016/j.jtocrr.2024.100675. eCollection 2024 Sep. JTO Clin Res Rep. 2024. PMID: 39399157 Free PMC article.
Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S, Gelsomino F, Rinaldi R, Muccioli L, Comito F, Di Federico A, De Giglio A, Lamberti G, Andrini E, Mollica V, D'Angelo R, Baccari F, Zenesini C, Madia P, Raschi E, Cortelli P, Ardizzoni A, Guarino M. Rossi S, et al. Among authors: lamberti g. J Neurol. 2023 Jun;270(6):2975-2986. doi: 10.1007/s00415-023-11625-1. Epub 2023 Feb 17. J Neurol. 2023. PMID: 36800019 Free PMC article.
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
Alessi JV, Wang X, Elkrief A, Ricciuti B, Li YY, Gupta H, Spurr LF, Rizvi H, Luo J, Pecci F, Lamberti G, Recondo G, Venkatraman D, Di Federico A, Gandhi MM, Vaz VR, Nishino M, Sholl LM, Cherniack AD, Ladanyi M, Price A, Richards AL, Donoghue M, Lindsay J, Sharma B, Turner MM, Pfaff KL, Felt KD, Rodig SJ, Lin X, Meyerson ML, Johnson BE, Christiani DC, Schoenfeld AJ, Awad MM. Alessi JV, et al. Among authors: lamberti g. J Thorac Oncol. 2023 Nov;18(11):1524-1537. doi: 10.1016/j.jtho.2023.05.019. Epub 2023 May 27. J Thorac Oncol. 2023. PMID: 37247843 Free PMC article.
Novel therapeutic strategies for recurrent SCLC.
Moliner L, Zhang B, Lamberti G, Ardizzoni A, Byers LA, Califano R. Moliner L, et al. Among authors: lamberti g. Crit Rev Oncol Hematol. 2023 Jun;186:104017. doi: 10.1016/j.critrevonc.2023.104017. Epub 2023 May 5. Crit Rev Oncol Hematol. 2023. PMID: 37150311 Review.
331 results